The Hidden Operational Cost of Master Protocols

Master protocols have become one of the most talked-about innovations in clinical development. Basket trials, umbrella trials, and platform trials promise faster answers, shared infrastructure, and more efficient use of patients — all compelling pitches to investors and boards looking for capital efficiency. The scientific and statistical case for master protocols is well established at this point.

What gets less airtime is what these designs actually demand operationally, week to week, from the team running them. The efficiency master protocols promise at the portfolio level often masks a significant increase in complexity at the execution level. For a large pharma company with dedicated infrastructure, that complexity is absorbable. For a small or mid-size biotech evaluating whether to adopt a master protocol structure either as a sole sponsor or as a participant in a shared platform, the operational burden is frequently underestimated until the trial is already underway.

What Master Protocols Are

Three structures typically fall under the "master protocol" umbrella:

Each shares a common protocol chassis, standardized procedures, and often a shared control group or backbone infrastructure — all designed to reduce redundancy compared to running separate standalone trials.

The efficiency case is real. Shared infrastructure means fewer duplicate startup activities, shared control arms reduce placebo-exposed patients, and centralized biomarker screening can identify and route patients faster than serial single-trial screening. These are legitimate, well-documented benefits.

Where the Hidden Costs Show Up

1. Protocol Amendment Complexity

A standalone trial's protocol amendment is disruptive but contained: one protocol, one set of sites, one IRB/EC submission pathway. A master protocol amendment ripples across every active arm, every participating site, and potentially every sponsor in a shared platform. Adding a new arm, changing eligibility criteria for one biomarker subgroup, or modifying the shared control arm can trigger:

• Re-review by every site's IRB/EC, even sites not directly affected by the specific change
• Re-consent processes for patients already enrolled, depending on the nature of the change
• Coordination across multiple sponsors if it's a shared platform, each with their own legal, regulatory, and timeline pressures
• Version control challenges, tracking which sites and patients are operating under which protocol version at any given time

What would be a routine, two-week amendment cycle in a standalone trial can become a multi-month coordination exercise in a master protocol — particularly one with multiple sponsors.

2. Data Infrastructure and Statistical Complexity

Master protocols require data systems capable of handling multiple arms, shared and arm-specific endpoints, and — in adaptive platform designs — real-time or near-real-time data flow to support interim decisions about which arms continue. This is a materially different technical lift than a standard EDC build for a single-arm or simple two-arm trial. Randomization systems need to route patients correctly across a growing or shrinking number of arms, often based on biomarker results that arrive on their own timeline. Interim analysis infrastructure for platform trials needs to support arm-dropping decisions without compromising the statistical integrity of arms that continue. For a small biotech contributing one arm to a larger platform trial, this can be less burdensome since the platform sponsor typically owns much of this infrastructure. But it introduces a different cost: dependency. Your trial's timeline and data quality become partially dependent on a system and a set of governance decisions you don't control.

3. Biomarker Screening Logistics

Master protocols, especially basket and umbrella trials, live or die on biomarker-driven patient routing. This sounds clean in a trial schematic and is genuinely difficult to execute well. Common friction points:

• Screen failure rates can be high — patients often screened centrally for a biomarker before it's known whether a matching arm has open slots, meaning some patients test positive but have nowhere to go
• Turnaround time on biomarker assays needs to be fast enough that patients don't progress or lose eligibility while waiting for results — which often requires investment in rapid, centralized testing rather than relying on local pathology
• Pre-screening protocols add an administrative layer separate from the treatment protocol itself, with its own consent process and data collection
• Assay validation and consistency across sites and over the life of a long-running platform trial is a nontrivial quality burden, particularly if the assay itself evolves over the trial's lifespan

4. Site Burden and Training

Sites participating in master protocols are managing something structurally different from a standard trial. Site staff need to understand the full master protocol structure, not just the arm their patients might enter. Multiple consent forms are often needed: one for pre-screening/biomarker testing, and separate consents for each arm a patient might be assigned to. Investigator and coordinator turnover is more damaging because the institutional knowledge required to run them well is harder to transfer. Sites that are excellent at running conventional trials are not automatically excellent at running master protocol arms.

5. Governance and Decision-Making Overhead

Platform trials in particular introduce governance structures that don't exist in standalone trials: steering committees, independent data monitoring committees with authority to add or drop arms, and often a neutral trial coordinating body separate from any individual sponsor. This governance is necessary for scientific integrity, but it adds meeting cadence and coordination overhead across multiple sponsors, each with their own internal approval chains. For a sponsor used to making trial decisions independently, this loss of unilateral control is a real cultural adjustment, not just a paperwork issue.

6. Vendor and CRO Capability Gaps

Not every CRO has deep master protocol experience. Randomization and drug supply systems for multi-arm, adaptive designs require specialized technical capability. Biostatistics teams need experience with the specific statistical methods platform trials use (Bayesian adaptive randomization, for example). Project management for a master protocol is closer to program management across a portfolio than single-trial project management. Change orders and scope creep are common when a CRO underestimated the complexity of the design at bid time.

Why This Catches Small Biotechs Off Guard

• The pitch happens at the strategic level, the cost lands at the operational level. Board presentations describe master protocols in terms of statistical efficiency. The operational reality is felt by clinical operations staff months later, after the design is locked and budgets are set.
• Lean teams have no slack for added complexity. A ten-person clinical operations function cannot easily absorb the same relative increase in coordination burden that a large pharma infrastructure can.
• Budgets are often built on standalone-trial benchmarks. Without someone who has specifically run a master protocol before, budget models tend to underestimate biostatistics, data management, and site support resourcing.
• Joining someone else's platform feels lower-risk than it is. Contributing an arm to an existing platform looks simpler, but introduces dependency risk: your program's timeline is now partly hostage to governance decisions, data systems, and other sponsors' priorities you don't control.

Questions to Ask Before Committing to a Master Protocol Structure